Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Progressive divisions of multipotent neural progenitors generate late-born chandelier cells in the neocortex.

Sultan KT, Liu WA, Li ZL, Shen Z, Li Z, Zhang XJ, Dean O, Ma J, Shi SH.

Nat Commun. 2018 Nov 2;9(1):4595. doi: 10.1038/s41467-018-07055-7.

2.

The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - CADENCE-BZ: study protocol for a randomized controlled trial.

Ryan A, Baker A, Dark F, Foley S, Gordon A, Hatherill S, Stathis S, Saha S, Bruxner G, Beckman M, Richardson D, Berk M, Dean O, McGrath J, Group CW, Scott J.

Trials. 2017 Apr 7;18(1):165. doi: 10.1186/s13063-017-1908-5.

3.

Internal Cholinergic Regulation of Learning and Recall in a Model of Olfactory Processing.

de Almeida L, Idiart M, Dean O, Devore S, Smith DM, Linster C.

Front Cell Neurosci. 2016 Nov 8;10:256. eCollection 2016.

4.

N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms.

Rossell SL, Francis PS, Galletly C, Harris A, Siskind D, Berk M, Bozaoglu K, Dark F, Dean O, Liu D, Meyer D, Neill E, Phillipou A, Sarris J, Castle DJ.

BMC Psychiatry. 2016 Sep 15;16(1):320. doi: 10.1186/s12888-016-1030-3.

5.

A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis.

Davis J, Eyre H, Jacka FN, Dodd S, Dean O, McEwen S, Debnath M, McGrath J, Maes M, Amminger P, McGorry PD, Pantelis C, Berk M.

Neurosci Biobehav Rev. 2016 Jun;65:185-94. doi: 10.1016/j.neubiorev.2016.03.017. Epub 2016 Apr 9. Review.

6.

Antioxidant treatments for schizophrenia.

Magalhães PV, Dean O, Andreazza AC, Berk M, Kapczinski F.

Cochrane Database Syst Rev. 2016 Feb 5;2:CD008919. doi: 10.1002/14651858.CD008919.pub2. Review.

PMID:
26848926
7.

Basal forebrain dynamics during nonassociative and associative olfactory learning.

Devore S, Pender-Morris N, Dean O, Smith D, Linster C.

J Neurophysiol. 2016 Jan 1;115(1):423-33. doi: 10.1152/jn.00572.2015. Epub 2015 Nov 11.

8.

Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review.

Deepmala, Slattery J, Kumar N, Delhey L, Berk M, Dean O, Spielholz C, Frye R.

Neurosci Biobehav Rev. 2015 Aug;55:294-321. doi: 10.1016/j.neubiorev.2015.04.015. Epub 2015 May 6. Review.

9.

N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review.

Oliver G, Dean O, Camfield D, Blair-West S, Ng C, Berk M, Sarris J.

Clin Psychopharmacol Neurosci. 2015 Apr 30;13(1):12-24. doi: 10.9758/cpn.2015.13.1.12.

10.

Post-stroke depression therapy: where are we now?

Nabavi SF, Turner A, Dean O, Sureda A, Mohammad S.

Curr Neurovasc Res. 2014;11(3):279-89. Review.

PMID:
24852795
11.

The glutathione system: a new drug target in neuroimmune disorders.

Morris G, Anderson G, Dean O, Berk M, Galecki P, Martin-Subero M, Maes M.

Mol Neurobiol. 2014 Dec;50(3):1059-84. doi: 10.1007/s12035-014-8705-x. Epub 2014 Apr 22. Review.

PMID:
24752591
12.

Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications.

Anderson G, Berk M, Dean O, Moylan S, Maes M.

CNS Drugs. 2014 Jan;28(1):1-10. doi: 10.1007/s40263-013-0119-1. Review.

PMID:
24150993
13.

Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness.

Berk M, Dean O, Drexhage H, McNeil JJ, Moylan S, O'Neil A, Davey CG, Sanna L, Maes M.

BMC Med. 2013 Mar 18;11:74. doi: 10.1186/1741-7015-11-74. Review.

14.

Who's left? Symptoms of schizophrenia that predict clinical trial dropout.

Thompson J, Berk M, Dean O, Kohlmann K, Jeavons S, Bush A, Copolov D.

Hum Psychopharmacol. 2011 Dec;26(8):609-13. doi: 10.1002/hup.1253. Epub 2011 Dec 5.

PMID:
22143987
15.

The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial.

Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, Kohlmann K, Jeavons S, Hewitt K, Allwang C, Cobb H, Bush AI, Schapkaitz I, Dodd S, Malhi GS.

J Affect Disord. 2011 Dec;135(1-3):389-94. doi: 10.1016/j.jad.2011.06.005. Epub 2011 Jun 29.

PMID:
21719110
16.

Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Gerlach M, Bartoszyk GD, Riederer P, Dean O, van den Buuse M.

J Neural Transm (Vienna). 2011 Dec;118(12):1733-42. doi: 10.1007/s00702-010-0571-8. Epub 2011 Jan 21.

PMID:
21253782
17.

N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action.

Dean O, Giorlando F, Berk M.

J Psychiatry Neurosci. 2011 Mar;36(2):78-86. doi: 10.1503/jpn.100057. Review.

18.

Oxidative pathways as a drug target for the treatment of autism.

Villagonzalo KA, Dodd S, Dean O, Gray K, Tonge B, Berk M.

Expert Opin Ther Targets. 2010 Dec;14(12):1301-10. doi: 10.1517/14728222.2010.528394. Epub 2010 Oct 18. Review.

PMID:
20954799
19.

Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats.

Choy KH, Dean O, Berk M, Bush AI, van den Buuse M.

Eur J Pharmacol. 2010 Dec 15;649(1-3):224-8. doi: 10.1016/j.ejphar.2010.09.035. Epub 2010 Sep 22.

PMID:
20868666
20.

Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia.

Berk M, Munib A, Dean O, Malhi GS, Kohlmann K, Schapkaitz I, Jeavons S, Katz F, Anderson-Hunt M, Conus P, Hanna B, Otmar R, Ng F, Copolov DL, Bush AI.

J Clin Psychiatry. 2011 Jul;72(7):909-13. doi: 10.4088/JCP.09m05741yel. Epub 2010 Sep 21.

PMID:
20868637

Supplemental Content

Loading ...
Support Center